News

Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway
Altimmune's Q1 2025 earnings call highlights breakthroughs in NASH treatments, robust financials with a new $100M credit facility, and imminent Phase ...
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development
CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...